121:315–328 DOI 10.1007/s10551-013-1723-1 Roche’s Clinical Trials with Organs from Prisoners: Does Profit Trump Morals? Judith Schrempf-Stirling Received: 17 August 2012 / Accepted: 5 April 2013 / Published online: 17 April 2013 Ó Springer Science+Business Media Dordrecht 2013 Abstract This case study discusses the economic‚ legal‚ and ethical considerations for conducting clinical trials in a controversial context. In 2010‚ pharmaceutical giant Roche received a shame award by the Swiss non-governmental
Premium Human rights Organ transplant Pharmaceutical industry
Bank of China Hong Kong ’s Initial Public Offering by Hugh Thomas Associate Professor of Finance The Chinese University of Hong Kong Draft of April 28‚ 2003 Accepted for publication in Journal of Financial Education. I am grateful to participants at the North American Case Research Institute 2002 conference in Banff‚ Canada‚ for their helpful comments and for research assistance from Wang Zhiqiang and Xu Zhi in preparing some tables. Please contact me at hugh-thomas@cuhk.edu
Premium Bank Hong Kong Hong Kong Stock Exchange
1) Why is Roche seeking to buy the 44% of Genentech it does not own? From Roche’s point of view‚ what are the advantages of owning 100% of Genentech? What are the risks? Roche is looking at this acquisition as a source of internal growth; the advantages are for research reasons‚ cutting cost creating a synergy by eliminating duplication of efforts and having easily access to Genentech’s free cash flow optimizing tax issues. Some analyst are concern that Genentech would lose its independence
Premium Stock market Stock Shareholder
Roche Holding AG: Funding the Genentech Acquisition Financial Policy March 5‚ 2015 Morgan Ephriam Kristopher Kirkpatrick Jasmine White 1. Statement of the Problem In the case Roche Holding AG: Funding the Acquisition‚ Roche and Genentech are interested in an acquisition. Roche is acquiring about receiving all outstanding shares of Genentech. Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. It discovers‚ develops and provides diagnostic and therapeutic products
Premium Bond Discounted cash flow Finance
Advanced Corporate Finance Final Case: Roche 1 2 Reasons for Roche’s 100% ownership of Genentech Since Roche and Genentech both operate in the pharmaceutical industry‚ but still have their own specialty‚ they can benefit from a partnership. Roche owns a majority stake in Genentech since 1990 and since 2007‚ it owns 56% of Genentech. Genentech was founded in 1976‚ their focus lies on biotechnology in which they are the second largest firm of the world. Genentech had become an important
Premium Corporate finance Debt Finance
Case Sustainability Initiative at Roche Table of Contents Introduction 3 Sustainable development: the triple bottom line 3 Economic‚ social and environmental responsibility 3 Social responsibility: the key elements 5 Corporate Responsibility Innovation at Roche 5 What is corporate responsibility? 5 Corporate responsibility according to the Roche corporate brochure 6 Target of responsibility as reflected in reported organizational structures‚ policies and practices. 7 Gaining competitive
Premium Sustainability Corporate social responsibility Business ethics
People’s Bank of China The People’s Bank of China is the is the central bank of People’s Republic of China with the power to control monetary policy and regulate the financial institutions in mainland China. The People’s Bank of China has more financial assets than any other single public finance institution in world history. History: The bank was established on December 1‚ 1948 based on consolidation of Huabei Bank‚ the Beihai Bank and the Xibei Farmer Bank. The headquarter was first located
Premium Bank
China Merchants Bank----the First Stock Commercial Bank in China ---- Interpret the Safety & Profitability Index Page 1. Brief 1.1 SMART objective of the project In this project‚ I will spend three months to investigating China Merchants Bank (CMB) financial situation‚ and interpret the financial statement of China Merchants Bank from 2004 to 2008 to evaluate the safety and profitability of CMB. Usual analysis tool conclude ratio analysis‚ primary
Premium Bank
Leadership of Bank of China (Employee / Labor Relations) Introduction of the Bank of China The place where I had completed my internship is Bank of China‚ which is one of the most influential and high-ranking banks in China‚ even in the world. Its long term reputation and credibility obtained from the global industry‚ customers and widely recognized authority. According to some global financial rankings in 2003‚ based on its core capital among the bankers‚ the bank of China was the 15th largest bank in the
Premium Leadership Decision making
acquisition of Genentech 1. Roche is seeking to acquire the 44% of Genentech that it doesn’t own yet because it would create new opportunities for Roche and the ability to work together on a much broader scale. Also‚ Roche’s managers were highly aware that in 2015 their product licensing agreement with Genentech was going to expire. This agreement previously gave Roche the accessibility to many of Genentech’s new innovative products through research and development. If Roche were to acquire the rest
Premium Stock Stock market Corporate finance